Michal Sladkowski
@msladkowski.bsky.social
Advanced Pharmacist in Oncology
MSc (Oncology), IP, PGDip, MPharm
@bopa.org.uk committee Vice Chair Elect, co-secretary and E&T co-chair
Let's Talk About SACT podcast host.
FRCR part 1 examiner
Breast and gynaecological cancers
MSc (Oncology), IP, PGDip, MPharm
@bopa.org.uk committee Vice Chair Elect, co-secretary and E&T co-chair
Let's Talk About SACT podcast host.
FRCR part 1 examiner
Breast and gynaecological cancers
Reposted by Michal Sladkowski
#MASCC25 may be over, but you can access all of the abstracts through Supportive Care in Cancer: link.springer.com/article/10.1...
The abstracts are available open-access across 25 categories, covering the full spectrum of recent research in supportive care.
#SuppOnc #SurvOnc #PallOnc #GlobOnc
The abstracts are available open-access across 25 categories, covering the full spectrum of recent research in supportive care.
#SuppOnc #SurvOnc #PallOnc #GlobOnc
July 7, 2025 at 5:37 PM
Reposted by Michal Sladkowski
Delighted to be sharing some work we have been working on for sometime:
Cetuximab Vs Pantitumumab - we found no efficacy difference but did find different side effect profile. Presenting at #ESMOGI25 this week
doi.org/10.6084/m9.f...
I'll be near the poster Friday PM if anyone wants to talk
Cetuximab Vs Pantitumumab - we found no efficacy difference but did find different side effect profile. Presenting at #ESMOGI25 this week
doi.org/10.6084/m9.f...
I'll be near the poster Friday PM if anyone wants to talk
July 2, 2025 at 10:30 AM
Delighted to be sharing some work we have been working on for sometime:
Cetuximab Vs Pantitumumab - we found no efficacy difference but did find different side effect profile. Presenting at #ESMOGI25 this week
doi.org/10.6084/m9.f...
I'll be near the poster Friday PM if anyone wants to talk
Cetuximab Vs Pantitumumab - we found no efficacy difference but did find different side effect profile. Presenting at #ESMOGI25 this week
doi.org/10.6084/m9.f...
I'll be near the poster Friday PM if anyone wants to talk
Reposted by Michal Sladkowski
#BOPA is seeking an enthusiastic and forward-thinking pharmacy professional to lead our flagship Let’s Communicate Cancer #LCC project
This is a unique opportunity to lead a nationally recognised, award-winning education programme
bopa.org.uk/vacancy-bopa...
#LetsCommunicateCancer
This is a unique opportunity to lead a nationally recognised, award-winning education programme
bopa.org.uk/vacancy-bopa...
#LetsCommunicateCancer
May 7, 2025 at 7:03 PM
#BOPA is seeking an enthusiastic and forward-thinking pharmacy professional to lead our flagship Let’s Communicate Cancer #LCC project
This is a unique opportunity to lead a nationally recognised, award-winning education programme
bopa.org.uk/vacancy-bopa...
#LetsCommunicateCancer
This is a unique opportunity to lead a nationally recognised, award-winning education programme
bopa.org.uk/vacancy-bopa...
#LetsCommunicateCancer
Reposted by Michal Sladkowski
NEWS FROM INDUSTRY🚨 Source AstraZeneca
DESTINY-Breast11 Update
DESTINY-Breast11 sees trastuzumab deruxtecan followed by paclitaxel, trastuzumab, and pertuzumab improved pathologic complete response rates compared to the standard neoadjuvant regimen
www.astrazeneca.com/media-centre...
DESTINY-Breast11 Update
DESTINY-Breast11 sees trastuzumab deruxtecan followed by paclitaxel, trastuzumab, and pertuzumab improved pathologic complete response rates compared to the standard neoadjuvant regimen
www.astrazeneca.com/media-centre...
May 7, 2025 at 8:59 AM
NEWS FROM INDUSTRY🚨 Source AstraZeneca
DESTINY-Breast11 Update
DESTINY-Breast11 sees trastuzumab deruxtecan followed by paclitaxel, trastuzumab, and pertuzumab improved pathologic complete response rates compared to the standard neoadjuvant regimen
www.astrazeneca.com/media-centre...
DESTINY-Breast11 Update
DESTINY-Breast11 sees trastuzumab deruxtecan followed by paclitaxel, trastuzumab, and pertuzumab improved pathologic complete response rates compared to the standard neoadjuvant regimen
www.astrazeneca.com/media-centre...
Reposted by Michal Sladkowski
The E&T subcommittee are pleased to announce that our new e-learning module for myeloma is now live on the BOPA website.
The module can be accessed under Haematology in the Courses & E-learning section.
www.bopa.org.uk/new-elearnin...
#BOPA #Myeloma #elearning #Haematology
The module can be accessed under Haematology in the Courses & E-learning section.
www.bopa.org.uk/new-elearnin...
#BOPA #Myeloma #elearning #Haematology
May 3, 2025 at 7:13 AM
The E&T subcommittee are pleased to announce that our new e-learning module for myeloma is now live on the BOPA website.
The module can be accessed under Haematology in the Courses & E-learning section.
www.bopa.org.uk/new-elearnin...
#BOPA #Myeloma #elearning #Haematology
The module can be accessed under Haematology in the Courses & E-learning section.
www.bopa.org.uk/new-elearnin...
#BOPA #Myeloma #elearning #Haematology
Reposted by Michal Sladkowski
🏆 📈 🙌 'Let's Talk About SACT' BOPA podcast are in the TOP 40 pharmacology Podcasts worldwide!
🙏 to our listeners, guests, and supporters! Your continued support makes this recognition possible.
🎧 🔗 Tune in here: www.millionpodcasts.com/pharmacology...
#pharmacypodcast #LetsTalkAboutSact #BOPA
🙏 to our listeners, guests, and supporters! Your continued support makes this recognition possible.
🎧 🔗 Tune in here: www.millionpodcasts.com/pharmacology...
#pharmacypodcast #LetsTalkAboutSact #BOPA
May 2, 2025 at 12:07 PM
🏆 📈 🙌 'Let's Talk About SACT' BOPA podcast are in the TOP 40 pharmacology Podcasts worldwide!
🙏 to our listeners, guests, and supporters! Your continued support makes this recognition possible.
🎧 🔗 Tune in here: www.millionpodcasts.com/pharmacology...
#pharmacypodcast #LetsTalkAboutSact #BOPA
🙏 to our listeners, guests, and supporters! Your continued support makes this recognition possible.
🎧 🔗 Tune in here: www.millionpodcasts.com/pharmacology...
#pharmacypodcast #LetsTalkAboutSact #BOPA
Reposted by Michal Sladkowski
Today is the day!
BOPA Introduction to Cancer Course 2025 is at Leeds.
Join us, Catherine Parbutt, Tasneem Ganijee and our excellent speakers today and tomorrow.
Plenty of high-quality teaching and learning over the next two days.
#BOPA #BOPAITC #cancerpharmacy #cancer #pharmsky #oncsky #haemsky
BOPA Introduction to Cancer Course 2025 is at Leeds.
Join us, Catherine Parbutt, Tasneem Ganijee and our excellent speakers today and tomorrow.
Plenty of high-quality teaching and learning over the next two days.
#BOPA #BOPAITC #cancerpharmacy #cancer #pharmsky #oncsky #haemsky
May 1, 2025 at 7:35 AM
Reposted by Michal Sladkowski
The #BOPA Introduction to #Cancer course is back for 2025!
New name ✅
New agenda ✅
New speakers ✅
New high quality content ✅
Have your coffee ☕️, card 💳 & mouse🖱️ ready next Thursday (6th) at 9am ⏰
Don’t forget to request study leave in advance!
#BOPAITC #ITC2025
#PharmSky #OncoSky #HaemSky #CanSky
New name ✅
New agenda ✅
New speakers ✅
New high quality content ✅
Have your coffee ☕️, card 💳 & mouse🖱️ ready next Thursday (6th) at 9am ⏰
Don’t forget to request study leave in advance!
#BOPAITC #ITC2025
#PharmSky #OncoSky #HaemSky #CanSky
🪫 SAVE THE DATE 🪫
BOPA Introduction to Cancer Two Day Course
📅Date: 1st & 2nd May, in Leeds
💰Cost: £50 as a contribution to the running of the course
🧑🏫Registration: Opens 9am on Thursday 6th March
#BOPAITC #ITC2025
www.bopa.org.uk/save-the-dat...
BOPA Introduction to Cancer Two Day Course
📅Date: 1st & 2nd May, in Leeds
💰Cost: £50 as a contribution to the running of the course
🧑🏫Registration: Opens 9am on Thursday 6th March
#BOPAITC #ITC2025
www.bopa.org.uk/save-the-dat...
February 28, 2025 at 9:47 PM
Reposted by Michal Sladkowski
We can’t wait to welcome everyone to Belfast this year! The programme is already looking amazing and the awards dinner is back at the iconic Titanic Museum!
For more information click on the link in the BOPA post and save the date now!
#BOPA2025 #Belfast
For more information click on the link in the BOPA post and save the date now!
#BOPA2025 #Belfast
SAVE THE DATE: The 28th BOPA Annual Conference #BOPA2025
Date: 3rd-5th October
Location: ICC Belfast
Cost: #BOPA members receive a reduced conference fee of £300 (including VAT) if booked by Monday 8th September
For more info www.bopa.org.uk/save-the-dat...
Date: 3rd-5th October
Location: ICC Belfast
Cost: #BOPA members receive a reduced conference fee of £300 (including VAT) if booked by Monday 8th September
For more info www.bopa.org.uk/save-the-dat...
January 19, 2025 at 10:43 PM
Reposted by Michal Sladkowski
Exciting opportunity to join us in York as we expand our lovely, friendly little team! Please contact if you'd like more information 😊 @bopa.org.uk
www.healthjobsuk.com/job/v6902478...
www.healthjobsuk.com/job/v6902478...
Job vacancy: Senior Pharmacist - Haematology, York and Scarborough Teaching Hospitals NHS Foundation Trust, York | trac.jobs
www.healthjobsuk.com
January 8, 2025 at 2:41 PM
Exciting opportunity to join us in York as we expand our lovely, friendly little team! Please contact if you'd like more information 😊 @bopa.org.uk
www.healthjobsuk.com/job/v6902478...
www.healthjobsuk.com/job/v6902478...
Reposted by Michal Sladkowski
📢The BOPA digital subcommittee are looking for new members! We are looking for members who have a passion for getting information to people in different ways & who are willing to get involved 💻📝📧📱
To find out more, click the link
www.bopa.org.uk/bopa-digital...
To find out more, click the link
www.bopa.org.uk/bopa-digital...
a man speaking into a microphone with the words " come join us " behind him
ALT: a man speaking into a microphone with the words " come join us " behind him
media.tenor.com
January 10, 2025 at 9:13 PM
📢The BOPA digital subcommittee are looking for new members! We are looking for members who have a passion for getting information to people in different ways & who are willing to get involved 💻📝📧📱
To find out more, click the link
www.bopa.org.uk/bopa-digital...
To find out more, click the link
www.bopa.org.uk/bopa-digital...
Reposted by Michal Sladkowski
📌 PATINA: a Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + ET vs. Anti-HER2 Therapy + ET after Induction Treatment for Hormone Receptor-Positive (HR+)/HER-Positive Metastatic Breast Cancer
#SABCS24 #day3 @oncoalert.bsky.social
#SABCS24 #day3 @oncoalert.bsky.social
December 12, 2024 at 6:36 PM
📌 PATINA: a Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + ET vs. Anti-HER2 Therapy + ET after Induction Treatment for Hormone Receptor-Positive (HR+)/HER-Positive Metastatic Breast Cancer
#SABCS24 #day3 @oncoalert.bsky.social
#SABCS24 #day3 @oncoalert.bsky.social